Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis - NCT00407043-11563(Clinical Trial 155997)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Lynbrook |
|
State:
|
|
NY |
| Zip Code: |
|
11563 |
| Conditions: |
|
Dry Eye Disease - Keratoconjunctivitis Sicca |
| Purpose: |
|
To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry
eye.
It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the
stinging with cyclosporine administration and the dry eye signs and symptoms experienced
during the initiation of therapy.
|
| Study summary: |
|
Dry eye is an ocular surface disease that produces discomfort and irritation. Estimated
prevalence ranges from 20 million people in the US being affected with mild to moderate dry
eye, to as many as one out of every five Americans.
A growing body of evidence has associated ocular inflammation with the signs and symptoms of
dry eye.
Restasis is indicated to increase tear production in patients whose tear production is
presumed to be suppressed due to ocular inflammation associated with a condition called
keratoconjunctivitis sicca. The relief of dry eye signs and symptoms with Restasis therapy
is often delayed by 1 to 6 months from the initiation of therapy. Stinging on installation,
particularly when initiating therapy, has been reported.
Lotemax, an ophthalmic corticosteroid, targets inflammation with a unique, site-active
mechanism of action.Structural modifications associated with an ester ophthalmic steroid
make Lotemax highly lipid soluble, enhancing penetration into cells and enabling Lotemax to
exert anti-inflammatory activity within the eye. Lotemax is indicated for the treatment of
steroid responsive inflammatory conditions associated with the palpebral and bulbar
conjunctiva, cornea, and anterior segment of the globe. |
| Criteria: |
|
Inclusion Criteria:
- Between the ages of 30 and 80 inclusive.
- Has not worn contact lenses for at least 1 month prior to the study and agrees to not
wear contact lenses during study.
- Oral medications stable 1 month prior to study.
- Oral medications anticipated to be stable during 60 day study.
- Patient is in generally good & stable overall health.
- Patient likely to comply with eye drop regimen, study guidelines & study visits.
- Corneal stain > 1+ or Conjunctival stain > 1+ or OSDI equal or > 5 or using regular
artificial tears at least on average twice daily.
- Informed consent signed.
Exclusion Criteria:
- History of Stevens-Johnson Syndrome or Ocular Pemphigoid.
- Punctal plugs inserted or punctal cautery in the past 3 months.
- Intra-ocular surgery within 6 months or ocular laser surgery within 3 months.
- History of liver disease.
- Pregnant or lactating women.
- Severe clinical vitamin deficiencies or history of vitamin overdose.
- Highly variable vitamin intake.
- Unstable use of systemic or topical medications known to create dry eye.
- Corneal pathology, which could, of itself, cause an ocular surface disorder.
- Use of glaucoma medications, topical or oral.
- Unstable diabetes mellitus.
- Allergy or sensitivity to Lotemax, Restasis or the OTC Tear Supplement.
- Use of topical steroids or Restasis within the past 1 month.
- Use of other topical ocular agents other than tear replacements within the past 1
week. |
|
|
|
| Study is available at: |
|
Ophthalmic Consultants of Long Island
Lynbrook, NY 11563
United States
Primary Contact:
Eric Donnenfeld, MD
Email: eddoph@aol.com
Phone: 516-766-2519 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 21, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|